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Urinary Testosterone Response to Corticotrophin and Dexamethasone in Hirsute Women by R J Leigh MB mRcp, J A Fleetwood BSC ARIC, Professor R Hall MD FRCP and Professor A L Latner MD FRCP (Departments ofMedicine andofClinical Biochemistry, Royal Victoria Infirmary, Newcastle upon Tyne) Urinary testosterone excretion was studied in 28 hirsute women aged 16 to 39 years (mean 26) and in 10 control female subjects aged 22 to 36 years (mean 28). Twenty-four hour urine collections were made over an 8 or 10 day period (Fig 1) . Days I and 2 served as a control period. On each of Days 3 and 4, tetracosactrin depot 1 mg was administered intramuscularly. Following a twoday recovery period (days 5 and 6), dexamethasone 4 mg/day was given in divided doses for 2 or 4 days.
The excretion of urinary testosterone (ug/24 h) by the control subjects was 8.6±1.0 during the control period, 23.5± 3.8 on the second day of stimulation and 3.5±1.0 on the final day of suppression, and for the group of 28 patients was 18.7.±9.9, 57.4±29.2 and 7.7±4.6 for corresponding periods. Mean levels for the 28 patients as a group were significantly elevated for all three stages of the test procedure (all P values <0.01), compared to those of the control group (Fig 2) . On the basis of 95 % confidence limits for the results of the control subjects, twenty-four hirsute women had elevated basal levels (> 10.9 mg/24 h) and 19 Wof these also showed an exaggerated response to corticotrophin (>32.1 mg/24 h on Day 4); 11 of these 19 patients suppressed to within the suppression range for control subjects whilst 8 did not. Of 5 patients with an elevated basal urinary testosterone level but a normal response to ACTH, none suppressed with dexamethasone to within the normal suppression range.
No significant correlation was found between biochemically defined groups of patients and any clinical findings. It is suggested that those patients with elevated basal urinary testosterone levels showing an exaggerated response to ACTH stimulation may have an underlying adrenal abnormality.
